Showing 5821-5830 of 8909 results for "".
- Alastin to Present Study Results Demonstrating Anti-aging and Procedure Enhancement Results of TriHex Technologyhttps://practicaldermatology.com/news/alastin-to-present-study-results-demonstrating-effectiveness-of-trihex-technology-for-post-laser-treatment-care/2458197/Alastin Skincare, Inc. will present data on three new studies at the 7th Annual Summit in Aesthetic Medicine meeting in Newport Beach, CA (May 5-7, 2017). "As part of our commitment to generate scientific data related to our Alastin Skincare products and technology, we have been work
- Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritishttps://practicaldermatology.com/news/pfizer-announces-us-fda-filing-acceptance-of-supplemental-new-drug-application-for-xeljanz-tofacitinib-citrate-for-the-treatment-of-adult-patients-wit/2458195/(via BusinessWire) Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has accepted for rev
- BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acnehttps://practicaldermatology.com/news/biopharmx-reports-positive-topline-results-of-bpx-01-topical-minocycline-for-acne/2458198/BioPharmX Corporation’s topical minocycline for acne, BPX-01, achieved its primary endpoint in a phase 2b clinical trial. There were statistically significant reductions in non-nodular inflammatory acne lesions when compared to vehicle in both the 1 percent and 2 percent doses of BP
- Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosahttps://practicaldermatology.com/news/abeona-therapeutics-provides-update-on-eb-101-gene-therapy-for-severe-form-of-epidermolysis-bullosa/2458202/Abeona Therapeutics, Inc. has announced updated clinical data from the ongoing Phase 1/2 clinical trial for the EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe fo
- Nutrition for Healing Introduces MEND Cosmetic to Support Improved Healing & Recovery From Cosmetic Surgeryhttps://practicaldermatology.com/news/nutrition-for-healing-introduces-mend-cosmetic-to-support-improved-healing-recovery-from-cosmetic-surgery/2458201/Nutrition For Healing LLC launched its new MEND Cosmetic, which is now available through cosmetic surgeons worldwide. The all natural formula, a blend of clinically researched, proven ingredients designed specifically to support healing from cosmetic surgery,
- Foamix Announces Additional Phase 3 Trial for FMX101 in Moderate to Severe Acnehttps://practicaldermatology.com/news/foamix-announces-additional-phase-3-trial-for-fmx101-in-moderate-to-severe-acne/2458203/Foamix Pharmaceuticals is launching an additional Phase 3 trial for FMX101 in moderate to severe acne, a topical minocycline treatment. If the results are positive, this new Phase 3 trial is expected to form the basis for a New Drug Application (NDA) which the company plans to submit in t
- Forging Ahead For Clear-Cut Best Practices for MOHS Surgeryhttps://practicaldermatology.com/news/forging-ahead-for-clear-cut-best-practices-for-mohs-surgery/2458204/New research on the average number of surgical slices made during Mohs micrographic surgery (MMS) will serve as a first step towards identifying best practices for MMS, as well as identifying and informing physicians who may need re-training because their practice patterns deviate far from their
- Allergan Officially Adds Coolsculpting to Portfoliohttps://practicaldermatology.com/news/allergan-adds-coolsculpting-to-portfolio/2458207/It’s a done deal. Allergan now owns ZELTIQ® Aesthetics. Allergan acquired ZELTIQ® Aesthetics for approximately $2.4 billion in cash. ZELTIQ® stockholders approved the transaction during its stockholder meeting h
- ASA Honors Researchers At Annual Meeting of the Society for Investigative Dermatologyhttps://practicaldermatology.com/news/asa-honors-researchers-at-annual-meeting-of-the-society-for-investigative-dermatology/2458208/Richard Edelson, MD Chair and Professor, Department of Dermatology, Yale School of Medicine, took home the David Martin Carter Mentor Award from the American Skin Association at the Annual Meeting of the
- Non-Invasive Pigmented Lesion Assay Almost Doubles Biopsy Specificityhttps://practicaldermatology.com/news/use-of-non-invasive-pigmented-lesion-assay-almost-doubles-biopsy-specificity/2458209/Dermatologists who incorporate Dermtech’s noninvasive pigmented lesion assay will biopsy fewer benign pigmented skin lesions and miss fewer melanomas, according to a new study in JAMA Dermatology